613P - PPPP1R13L variant associated with prognosis for patients with rectal cancer

Date 01 October 2012
Event ESMO Congress 2012
Session Poster presentation III
Topics Translational Research
Colon and Rectal Cancer
Basic Principles in the Management and Treatment (of cancer)
Presenter Jong Gwang Kim
Authors J.G. Kim1, B.W. Kang2, S.J. Lee2, Y. Lee2, Y.S. Chae1
  • 1Hematology/oncology, kyungpook National University Medical Center, Daegu/KR
  • 2Oncology/hematology, kyungpook National University Medical Center, Daegu/KR



Genetic variants related to apoptosis and DNA repair pathways may play a meaningful role in cancer progression as well as carcinogenesis. Among them, ERCC1 and PPP1R13L polymorphisms was shown to synergistically affect these pathways. The aim of this study was to investigate the association between these genetic variants and prognosis of colorectal cancer (CRC) operated curatively.


A total of 349 CRC patients underwent curative surgery were consecutively enrolled between March 2003 and August 2006. DNA was extracted from fresh frozen normal tissue and each polymorphism (ERCC1 rs11615 and rs735482; PPP1R13L rs1005165 and rs967591) was genotyped by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).


No statistical significance between these 4 variants and survival in a multivariate analysis for all CRC patients. However, the CC genotype of the PPP1R13L rs1005165 was significantly associated with worse survival in 164 patients with rectal cancer (HR = 2.10 and P = 0.037 for RFS; HR = 2.27 and P = 0.039 for DSS, respectively) as a recessive model of the C allele in a multivariate analysis. Meanwhile, no statistical differences in clinicopathologic characteristics were observed according to the PPPIR13L rs1005165 genotype in patients with rectal cancer.


Our results suggest that PPP1R13L rs1005165 variant is possible prognostic marker for patients with rectal cancer.


All authors have declared no conflicts of interest.